Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Acalabrutinib Plus BR Leads to High CR Rates in Treatment-Naive, Relapsed/Refractory MCL

June 9th 2023

The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.

Dr Phillips on the Investigation of Acalabrutinib/Benendamustine/Rituximab in MCL

June 7th 2023

Tycel Phillips, MD, MPH, discusses the safety and efficacy of acalabrutinib plus bendamustine and rituximab from a phase 1 trial in patients with treatment-naive and relapsed/refractory mantle cell lymphoma.

Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31st 2023

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

Overview of Mantle Cell Lymphoma

May 31st 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.

Dr Phillips on the Implications of the FDA Approval of Pirtobrutinib in R/R Mantle Cell Lymphoma

May 23rd 2023

Tycel Phillips, MD, MPH, discusses the implications of the FDA approval of pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Phillips on Treatment After Progression on a BTK Inhibitor in MCL

May 22nd 2023

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

Analysis Determines Predictive Biomarkers for Lenalidomide Survival Benefits in Mantle Cell Lymphoma

May 19th 2023

Polymorphic alleles of ABCB1 or VEGF were predictive of lenalidomide efficacy in patients with mantle cell lymphoma who received lenalidomide maintenance after autologous stem cell transplant.

Dr Habermann on Ongoing Trials in MCL and MZL

May 16th 2023

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

Ibrutinib-Containing Regimens Remain of Interest Despite Agent’s Withdrawal in MCL and MZL

May 16th 2023

Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.

Dr Habermann on Data Leading to the Withdrawal of Ibrutinib in MCL

May 16th 2023

Thomas M. Habermann, MD, discusses the data that led to the decision to withdraw the indication for ibrutinib for the treatment of patients with mantle cell lymphoma.

Dr Habermann on the Withdrawal of U.S. Indications for Ibrutinib in MCL and MZL

May 12th 2023

Thomas M. Habermann, MD, discusses the withdrawal of United States indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Dr Habermann on the Evolving Treatment Landscape of Mantle Cell Lymphoma

May 8th 2023

Thomas M. Habermann, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Venetoclax Plus Lenalidomide/Rituximab Regimen Delivers Safety, Efficacy in Untreated Mantle Cell Lymphoma

May 8th 2023

The addition of venetoclax to lenalidomide and rituximab produced early evidence of clinical efficacy with a tolerable safety profile in previously untreated patients with mantle cell lymphoma.

Liso-cel Induces Statistically Significant Responses in R/R Follicular Lymphoma and Mantle Cell Lymphoma

May 1st 2023

Lisocabtagene maraleucel elicited statistically significant and clinically meaningful responses in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma, meeting the primary end point of the phase 2 TRANSCEND FL and phase 1 TRANSCEND NHL 001 trials, respectively.

Dr Epstein-Peterson on the Use of CAR T-Cell Therapy in MCL

April 7th 2023

Zachary Epstein-Peterson, MD, discusses the use of CAR T-cell therapy in mantle cell lymphoma and highlights questions that remain to be answered within the treatment landscape.

AbbVie Withdraws Ibrutinib MCL and MZL Indications in the United States

April 7th 2023

AbbVie has announced the intention to voluntarily withdraw indications for ibrutinib in patients with mantle cell lymphoma who have previously received at least 1 therapy and in those with marginal zone lymphoma who require systemic treatment and have received at least 1 prior anti–CD20-based therapy.

Dr Epstein-Peterson on the Treatment of Transplant-Eligible and -Ineligible Patients with MCL

April 6th 2023

Zachary Epstein-Peterson, MD, discusses available treatment approaches for patients with mantle cell lymphoma who are transplant eligible or ineligible.

Dr Shah on the Investigation of LV20.19 CAR in MCL

April 5th 2023

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Venetoclax Induces Notable ORR But Short PFS in High-Risk Mantle Cell Lymphoma

April 5th 2023

Venetoclax, alone or in combination with a BTK inhibitor, improved overall response rate in patients with pretreated, high-risk mantle cell lymphoma, according to findings from a retrospective study. However, the BCL-2 inhibitor was associated with short durations of progression-free survival.

Acalabrutinib Receives Approval in China for Relapsed/Refractory Mantle Cell Lymphoma

March 23rd 2023

Acalabrutinib has received conditional approval from the National Medical Products Administration in China for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.